• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Merus N.V. - Common Shares (NQ: MRUS )

    42.07 -1.03 (-2.39%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Merus N.V. - Common Shares

    < Previous 1 2 3 Next >
    Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
    From Merus N.V.
    Via GlobeNewswire
    Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
    From Merus N.V.
    Via GlobeNewswire
    Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
    From Merus N.V.
    Via GlobeNewswire
    Merus to Present at Upcoming Investor Conferences
    From Merus N.V.
    Via GlobeNewswire
    Merus Receives FDA extension of PDUFA for zenocutuzumab
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
    Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation 
    From Merus N.V.
    Via GlobeNewswire
    Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
    Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback 
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
    From Merus N.V.
    Via GlobeNewswire
    Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
    From Merus N.V.
    Via GlobeNewswire
    Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Pricing of Upsized Public Offering of Common Shares
    From Merus N.V.
    Via GlobeNewswire
    Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
    From Merus N.V.
    Via GlobeNewswire
    Merus N.V. Announces Proposed Public Offering of Common Shares
    From Merus N.V.
    Via GlobeNewswire
    Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
    If approved, Zeno will be the first targeted therapy for NRG1+ cancer 
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
    From Merus N.V.
    Via GlobeNewswire
    Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
    From Merus N.V.
    Via GlobeNewswire
    Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
    From Gilead Sciences, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.